The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics

UMR U557 Inserm, U1125 Inra, Cnam, Université Paris 13, CRNH IdF, F-93017 Bobigny, France.
Trials (Impact Factor: 2.12). 02/2008; 9:35. DOI: 10.1186/1745-6215-9-35
Source: PubMed

ABSTRACT During the last decades, many basic and clinical research have pointed to the role of B vitamins (folate, vitamins B6 and B12) and n-3 fatty acids as nutritional factors that might have a protective effect on the development of cardiovascular diseases (CVD).
The SU.FOL.OM3 (SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids) trial is a randomized double-blind, placebo-controlled, secondary-prevention trial designed to test the efficacy of 5-methyl tetra-hydro-folates (5-MTHF) supplementation, in combination with vitamin B6 and B12 and/or n-3 fatty acids, at nutritional doses, on fatal and non fatal ischemic CVD in a 2 x 2 factorial design. A total of 2501 patients aged between 45 and 80 years who had a past history, in the previous year, of myocardial infarction (n = 1151) or instable angina pectoris (n = 711) or an ischemic stroke (n = 639) were included. Subjects have to be supplemented and followed up for five years. Daily supplementation comprised nutritional doses of 5-MTHF (560 microgram), vitamin B6 (3 mg) and B12 (20 microgram) and/or n-3 fatty acids (600 mg with an EPA:DHA ratio of 2:1). A factorial design 2 x 2 has been applied to investigate the separate effects of the B-vitamins, and the n-3 fatty acids, as well as their interaction as compared to the placebo.The primary endpoint is a combination of myocardial infarction, ischemic stroke and cardiovascular death. Secondary endpoints are events of the composite endpoint taken separately, total mortality, and other cardiovascular events such as acute coronary syndromes, coronary revascularization, cardiac failure, arrhythmia...
Baseline socio-demographic and medical characteristics of participants are totally comparable in the four randomized groups.
Current Controlled Trials ISRCTN41926726.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating homocysteine levels (tHcy), a product of the folate one carbon metabolism pathway (FOCM) through the demethylation of methionine, are heritable and are associated with an increased risk of common diseases such as stroke, cardiovascular disease (CVD), cancer and dementia. The FOCM is the sole source of de novo methyl group synthesis, impacting many biological and epigenetic pathways. However, the genetic determinants of elevated tHcy (hyperhomocysteinemia), dysregulation of methionine metabolism and the underlying biological processes remain unclear. We conducted independent genome-wide association studies and a meta-analysis of methionine metabolism, characterized by post-methionine load test tHcy, in 2,710 participants from the Framingham Heart Study (FHS) and 2,100 participants from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial, and then examined the association of the identified loci with incident stroke in FHS. Five genes in the FOCM pathway (GNMT [p = 1.60×10-63], CBS [p = 3.15×10-26], CPS1 [p = 9.10×10-13], ALDH1L1 [p = 7.3×10-13] and PSPH [p = 1.17×10-16]) were strongly associated with the difference between pre- and post-methionine load test tHcy levels (ΔPOST). Of these, one variant in the ALDH1L1 locus, rs2364368, was associated with incident ischemic stroke. Promoter analyses reveal genetic and epigenetic differences that may explain a direct effect on GNMT transcription and a downstream affect on methionine metabolism. Additionally, a genetic-score consisting of the five significant loci explains 13% of the variance of ΔPOST in FHS and 6% of the variance in VISP. Association between variants in FOCM genes with ΔPOST suggest novel mechanisms that lead to differences in methionine metabolism, and possibly the epigenome, impacting disease risk. These data emphasize the importance of a concerted effort to understand regulators of one carbon metabolism as potential therapeutic targets.
    PLoS Genetics 03/2014; 10(3):e1004214. DOI:10.1371/journal.pgen.1004214 · 8.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Blood pressure (BP) variability is associated with several cardiovascular (CV) risk factors. Is BP variability measurement of any additive value, in terms of CV risk assessment strategies? To answer this question, we analyzed data from the SU.FOL.OM3 secondary prevention trial that included 2501 patients with background of CV disease history (coronary or cerebrovascular disease). BP was measured every year allowing calculation of variability of BP, expressed as s.d. and coefficient of variability (s.d./mean systolic BP) in 2157 patients. We found that systolic BP variability was associated with several CV risk factors: principally hypertension, age, and diabetes. Furthermore, all antihypertensives were positively associated with variability. Logistic regression analysis revealed that three factors were independent predictors of major CV event: coefficient of variability of systolic BP (OR=1.23 per s.d., 95% CI: 1.04-1.46, P=0.016), current smoking (OR=1.94, 95% CI: 1.03-3.66, P=0.039), and inclusion for cerebrovascular disease (OR=1.92, 95% CI: 1.29-2.87, P=0.001). Finally, when comparing logistic regression models characteristics without, and then with, inclusion of BP variability, there was a modest but statistically significant improvement (P=0.04). In conclusion, age, BP and diabetes were the major determinants of BP variability. Furthermore, BP variability has an independent prognostic value in the prediction of major CV events; but improvement in the prediction model was quite modest. This last finding is more in favor of BP variability acting as an integrator of CV risk than acting as a robust independent CV risk factor in this high-risk population.Journal of Human Hypertension advance online publication, 3 July 2014; doi:10.1038/jhh.2014.44.
    Journal of Human Hypertension 07/2014; 29(2). DOI:10.1038/jhh.2014.44 · 2.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Riassunto. Attualmente la medicina è finalizzata soprattut-to alla cura delle lesioni. È opportuno, invece, sviluppare il concetto di "cura della salute". Numerose autorità scientifi-che raccomandano un incremento dell'assunzione di acidi grassi essenziali omega-3 e di astaxantina per il manteni-mento della salute della popolazione generale. Gli omega-3 sono necessari per il potenziamento funzionale delle membrane cellulari, sia nel soggetto sano, sia in affetti da di-verse patologie croniche. È noto quanto benefico risulti un frequente, regolare consumo di pesce, alimento che è ricca sorgente di omega-3. L'astaxantina è dotata di una potente azione antiossidante comprovata in lavori sperimentali ed in studi clinici. Per la recente evidenza della contemporanea presenza di omega-3 e astaxantina in olio di salmone sel-vaggio Sockeye, è stata effettuata una revisione della lette-ratura al fine di valutare il possibile ruolo di tale associazio-ne nell'ambito di programmi per la promozione della salute. Parole chiave. Astaxantina, cura della salute, olio di sal-mone selvaggio Sockeye, omega-3, patologie croniche. Summary. Omega-3 fatty acids and astaxanthin in health and disease. Recent knowledges. At present, medicine is aimed to the treatment of lesions. Instead, it would be right to develop the maintenance of normal health. A number of authorities have recently rec-ommended increases in intake of omega-3 fatty acids and astaxanthin for the health of general population. Omega-3 are necessary to provide the optimal function of cellular membrane in health and in disease states. It is well known how at least two servings of fish a week, or dietary supple-mentation of fatty acids omega-3, should be taken to ob-tain the health benefits of this essential nutrient. Astaxan-thin is a powerful biological antioxidant. This property has been implicated in its various biological activities demon-strated in both experimental animals and clinical studies. For the recent evidence of the contemporary presence of omega-3 and astaxanthin in oil of Wild Pacific Salmon Sock-eye, a review has been effected for the evaluation of a pos-sible role of such association for the health promotion.

Preview (3 Sources)

Available from